Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rockwell MedicalFRA:RWM 55 EV-to-EBITDA is -10.51 as of Aug. 19, 2026. GuruFocus rates FRA:RWM with a GF Score™ of 55/100 and a GF Value™ of €5.73 (Fairly Valued). The stock has 2 warning signs investors should review. Among 734 Drug Manufacturers companies, Rockwell Medical ranks worse than 136239.65% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Rockwell Medical's enterprise value is €16.79 Mil.
Rockwell Medical's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €-1.60 Mil. Therefore, Rockwell Medical's EV-to-EBITDA for today is -10.51.
The historical rank and industry rank for Rockwell Medical's EV-to-EBITDA or its related term are showing as below:
FRA:RWM'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -375.51 Med: -4.73 Max: 46.14
Current: -10.69
During the past 13 years, the highest EV-to-EBITDA of Rockwell Medical was 46.14. The lowest was -375.51. And the median was -4.73.
FRA:RWM's EV-to-EBITDA is ranked worse than 100% of 734
companies
in the Drug Manufacturers industry
Industry Median: 13.325
vs FRA:RWM: -10.69
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Rockwell Medical (FRA:RWM) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Rockwell Medical's PE Ratio (TTM) for today is calculated as:
Rockwell Medical's share price for today is €5.25.
Rockwell Medical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.152.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Rockwell Medical's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:RWM vs BTAI, MRMD, TXMD: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Rockwell Medical's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rockwell Medical EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rockwell Medical's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Rockwell Medical's EV-to-EBITDA falls into.
Rockwell Medical's current Enterprise Value is €16.79 Mil.
Rockwell Medical's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.60 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rockwell Medical (FRA:RWM) has a EV-to-EBITDA of -10.51 as of Aug. 19, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Rockwell Medical. According to the industry distribution chart, Rockwell Medical ranks #999999 out of 734 companies in the Drug Manufacturers industry.
Is Rockwell Medical's EV-to-EBITDA too high?
Rockwell Medical's current EV-to-EBITDA is -10.51. Based on the distribution chart, Rockwell Medical ranks #999999 out of 734 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Rockwell Medical has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Rockwell Medical's EV-to-EBITDA compare to BTAI and MRMD?
According to the Drug Manufacturers industry distribution chart, Rockwell Medical ranks #999999 out of 734 companies for EV-to-EBITDA. This places Rockwell Medical in the lower half of its industry. The industry median EV-to-EBITDA is 13.33. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.33, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Rockwell Medical. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rockwell Medical's current EV-to-EBITDA is -10.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rockwell Medical stock overvalued right now?
Based on GuruFocus' analysis, Rockwell Medical (FRA:RWM) is currently considered Fairly Valued. The stock's GF Value™ is €5.73, compared to a current price of €5.25 — trading 8.4% below its estimated fair value. The current EV-to-EBITDA is -10.51. Rockwell Medical's overall GF Score™ is 55/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Rockwell Medical (FRA:RWM), the current EV-to-EBITDA is -10.51 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rockwell Medical (FRA:RWM) Overvalued in 2026?
Based on GuruFocus' analysis, Rockwell Medical stock appears to be undervalued.
The current stock price of €5.25 is trading 8.4% below its estimated GF Value™ of €5.73.
GuruFocus considers Rockwell Medical to be Fairly Valued.
Key valuation signals for FRA:RWM:
EV-to-EBITDA: -10.51
GF Value™: €5.73 vs. price of €5.25 (8.4% below fair value)
No single metric tells the full story. See the FRA:RWM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, acid, and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate, among others. The company delivers the majority of its hemodialysis concentrates products and mixers to dialysis clinics throughout the United States and internationally, utilizing its own delivery trucks and third-party carriers.
55GF Score
Get the complete analysis for FRA:RWM
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RWM has been successfully added to your 
